Retatrutide South Africa: Guide, Dosage & 2026 Prices

Retatrutide is an investigational triple-agonist (GIP/GLP-1/glucagon) weight-loss peptide that, as of mid-2026, is not registered with SAHPRA and not yet FDA-approved, yet is openly sold across South Africa as a "research peptide" by vendors like New You Lab, Beskinny (HD Labs), and GLP1-2U at prices ranging roughly R1,200–R3,500 per vial because it sits outside the regulated medicines framework [4][5][15]. The clinical hook is hard to ignore: in the Jastreboff et al. Phase 2 NEJM trial (2023), participants on 12 mg weekly lost an average of 24.2% of body weight at 48 weeks—the largest placebo-adjusted reduction reported for any obesity drug to date, driven by simultaneous activation of three metabolic pathways rather than one or two [8]. This guide pairs that trial science with SA-specific product formats, the exact titration schedule from the NEJM supplementary appendix, and an honest read on where SAHPRA actually stands.

Key Takeaways

• Retatrutide activates three metabolic receptors (GLP-1, GIP, glucagon) simultaneously, producing ~24% mean body-weight loss at 12 mg weekly in Phase 2 trials—roughly double the effect of semaglutide monotherapy [8].
• It is not SAHPRA-registered and not FDA-approved as of mid-2026; South African vendors sell it as a "research peptide" outside the regulated medicines framework [4][5].
• Pre-filled pens cost R2,500–R5,000; lyophilised vials cost R600–R2,300 depending on milligrams and format [5].
• The Phase 2 titration protocol escalates 2 mg → 4 mg → 8 mg → 12 mg weekly over 16 weeks to minimise gastrointestinal side effects [4].
• Nausea (~66%), diarrhoea (~50%), and vomiting (~40%) dominate the adverse-event profile at 12 mg; discontinuation rates reach 10–15% due to GI intolerance [10].
• Semaglutide and tirzepatide are SAHPRA-registered Schedule 4 alternatives with established safety data; retatrutide carries unquantified risks from unverified manufacturing [1][9].

The sections below cover the mechanism behind retatrutide's triple-receptor action; how it compares to semaglutide and tirzepatide; current South African regulatory status and pricing; the Phase 2 dosage protocol; documented side effects; and where to source it locally.

What Is Retatrutide? The 60-Second Answer

Retatrutide (development code LY-3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly that activates three metabolic receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple action is why clinicians and peptide vendors call it the "Triple G" agonist. In the Phase 2 NEJM trial, the 12 mg arm produced 24.2% mean body-weight reduction at 48 weeks because all three receptor pathways suppress appetite, improve insulin response, and increase energy expenditure in parallel [6].

How It Differs From Semaglutide and Tirzepatide

The distinction is straightforward receptor arithmetic. Semaglutide (Ozempic, Wegovy, and SA-available variants like the Body Pharm Semaglutide 6 Pen or the HD Semaglutide 10 Pen) activates only the GLP-1 receptor. This produces appetite suppression and delayed gastric emptying but no direct metabolic rate boost. Tirzepatide (Mounjaro, Zepbound) activates GLP-1 and GIP, which is why it outperforms semaglutide on weight loss in head-to-head trials. Retatrutide adds glucagon-receptor activation on top of those two. Glucagon drives lipolysis and raises basal metabolic rate, so daily energy expenditure rises alongside the appetite-suppression and insulin effects already familiar from semaglutide and tirzepatide [6].

Regulatory Status in One Line

Retatrutide is not yet FDA-approved and not registered with SAHPRA as of mid-2026; it remains a late Phase 2 / early Phase 3 investigational compound because Eli Lilly has not filed a marketing application with either regulator [8][9].

How Does Retatrutide Work? Triple-Receptor Mechanism

Retatrutide produces weight loss by simultaneously activating three metabolic receptors—GLP-1, GIP, and glucagon—each contributing a distinct mechanism. GLP-1 activation suppresses appetite and slows gastric emptying by signalling satiety in the hypothalamus. GIP activation improves insulin response and modulates fat metabolism by improving post-meal glucose control. Glucagon activation increases energy expenditure and stimulates lipolysis by raising hepatic glucose output and basal metabolic rate. Together, these drove a 24.2% mean body-weight reduction in the 12 mg arm of the Phase 2 NEJM trial at 48 weeks [8].

What Each Receptor Does

GLP-1 (glucagon-like peptide-1) reduces caloric intake by signalling satiety in the hypothalamus and delaying gastric emptying. Food sits longer in the stomach and hunger returns later. This is the same single-receptor mechanism behind semaglutide products like the Body Pharm Semaglutide 6 Pen and the HD Semaglutide 10 Pen—which is why semaglutide monotherapy produces weight loss but at a lower magnitude than triple agonism [8]. GIP (glucose-dependent insulinotropic polypeptide) improves post-meal insulin secretion and modulates adipocyte function. Dual GLP-1/GIP agonists like tirzepatide outperform pure GLP-1 drugs on weight and HbA1c (glycated haemoglobin) endpoints in clinical trials [8]. Glucagon receptor activation is the mechanism retatrutide adds on top of the tirzepatide template. Glucagon increases hepatic glucose output and raises basal metabolic rate. It drives lipolysis in adipose tissue, so daily energy expenditure rises rather than the body adapting downward as it typically does during caloric restriction [8].

Why the Three Combine Non-Linearly

GLP-1 and GIP reduce intake; glucagon raises output. They hit different sides of the energy-balance equation. In Jastreboff et al., 2023, 12 mg retatrutide produced roughly double the weight loss seen with high-dose semaglutide monotherapy in comparable obesity trials because the triple mechanism addresses both sides of the caloric deficit simultaneously. The dose-response curve had not yet plateaued at 48 weeks [8][10]. That non-plateau is clinically interesting—it suggests the triple mechanism has more headroom than single or dual agonism before tolerability becomes the limiting factor. Higher doses might produce even larger losses if GI side effects can be managed [10].

Retatrutide vs Semaglutide vs Tirzepatide: 2026 Comparison

Retatrutide is the only triple GLP-1/GIP/glucagon receptor agonist of the three; semaglutide is a single GLP-1 agonist and tirzepatide is a dual GLP-1/GIP agonist [8]. That mechanistic gap is the main reason 48-week Phase 2 retatrutide data showed weight-loss figures roughly double those reported for high-dose semaglutide in comparable obesity populations. The glucagon arm adds a direct metabolic rate boost that semaglutide cannot provide [15][8]. The regulatory gap matters just as much as the pharmacology. Semaglutide and tirzepatide are SAHPRA-registered Schedule 4 prescription medicines in 2026; retatrutide is not registered with SAHPRA and has not been submitted to the FDA. Analysts project the earliest plausible US submission for 2027–2028 because Eli Lilly is still running Phase 3 trials [4][8][12].

Side-by-Side Snapshot (Mid-2026)

Feature	Semaglutide	Tirzepatide	Retatrutide
Mechanism	GLP-1 only	GLP-1 + GIP	GLP-1 + GIP + glucagon [8]
FDA status	Approved (2017/2021)	Approved (2022/2023)	Not submitted [8][12]
SAHPRA status	Registered, Schedule 4	Registered, Schedule 4	Not registered [4][9]
Peak trial weight loss (highest dose)	~15% at 68 wk	~21% at 72 wk	~24% at 48 wk, curve still climbing [15]
SA formats (2026)	Pre-filled pens, vials	Pre-filled pens, hybrid pens	Lyophilised vials, hybrid pens [1][2][7]
Approx. ZAR/month (research-grade)	R900–R1,800	R1,500–R2,800	R2,200–R4,500 [7]

For readers who want the approved-medicine route rather than the unregistered one, the Body Pharm Semaglutide 6 Pen and HD Semaglutide 10 Pen are the closest mechanistic cousins available locally. They will not match retatrutide's headline weight-loss numbers because they activate only one receptor instead of three. They do sit inside a regulated supply chain with labelled stability data—something no retatrutide product in South Africa currently offers [4][1].

Retatrutide in South Africa: SAHPRA Status Explained (2026)

Retatrutide is not a SAHPRA-registered medicine in South Africa as of mid-2026 and does not appear on the current Schedules to the Medicines and Related Substances Act because no marketing application has been filed with the regulator [1][2]. No local pharmacy can legally dispense it on a Schedule 4 script the way they would semaglutide or tirzepatide. No SAHPRA-approved patient information leaflet exists for any retatrutide product sold here [2][3].

What "Research Peptide" Actually Means Here

South African vendors such as New You Lab, Beskinny, and GLP1-2U market retatrutide as a "research peptide" or "research-grade" injection [4][5][9]. That label is a commercial convention, not a SAHPRA classification. The product sits outside the registered-medicines framework entirely: it is neither a scheduled prescription medicine nor an approved therapeutic. No SAHPRA media release in 2024–2026 has specifically authorised, scheduled, or banned it by name because the regulator has not formally assessed it [3]. Sellers position it for "laboratory use only" while customers use it on themselves. That is the grey zone every buyer should understand before paying.

The Legal Grey Area

Under the Medicines Act, human use of an unregistered medicine ordinarily requires a Section 21 authorisation or enrolment in an approved clinical trial [2]. Personal importation and "research use" purchases occupy ambiguous territory that has not been tested publicly against retatrutide specifically. No court case or regulatory enforcement action has clarified the boundaries. This article is not legal or medical advice. If certainty matters to you, confirm current status directly with SAHPRA [1][3] and speak to a registered prescriber. Readers who want a regulated alternative inside the Schedule 4 system can look at semaglutide products like the Body Pharm Semaglutide 6 Pen or the HD Semaglutide 10 Pen, both of which sit inside the registered-medicines channel [1].

Why This Could Change

Eli Lilly continues to develop retatrutide globally, with Phase 3 programmes ongoing through 2025–2026. No marketing application has been filed with SAHPRA or any African regulator as of mid-2026 because the company is still generating safety and efficacy data [11][15]. Analyst projections place the earliest realistic FDA submission around 2027–2028. African filings typically lag high-income markets by 2–4 years due to regulatory capacity and commercial prioritisation [17]. This section will be reviewed in Q3 2026.

Retatrutide Products Available in South Africa (2026)

Seven retatrutide formats are sold at Beskinny.store as of mid-2026, split between pre-filled pens (Body Pharm 32 mg, Body Pharm 64 mg, HD Labs 32 mg) and lyophilised vials (HD Labs 10 mg, HD Labs 32 mg, plus 5 mg and 10 mg vials bundled with bacteriostatic water) [5]. All are sold as research-grade peptides, not SAHPRA-registered medicines, because they fall outside the regulated supply chain [1][3].

Pen Formats: Pre-Mixed, Fixed Dose-Per-Click

Pens arrive already reconstituted and dose by click increment. This removes the maths and the syringe step. The Body Pharm Retatrutide 32 Pen carries 32 mg of active peptide across the cartridge; the 64 mg Body Pharm variant doubles the cartridge load for users titrating toward the 8–12 mg weekly maintenance ranges seen in the Jastreboff Phase 2 trial [8]. The HD Labs Retatrutide 32 Pen is HD's pen-format equivalent. Pens trade flexibility for convenience: you cannot adjust concentration, and once opened the clock starts on peptide stability because reconstituted peptides degrade over time at room temperature [8].

Vials: Cheaper Per mg, Reconstitution Required

Vials ship as dry lyophilised powder and require the user to add bacteriostatic water before drawing doses with insulin syringes. The HD Labs Retatrutide 10mg vial and 32 mg HD Labs vial are the main options, alongside 5 mg and 10 mg vials supplied with BAC water included. Vials let you set your own concentration—10 mg reconstituted in 2 mL gives 5 mg/mL, for example. This matters during the 2 mg → 4 mg → 8 mg titration ramps documented in the NEJM 2023 supplementary appendix because you can dial in precise weekly increments [9]. They demand sterile technique and arithmetic discipline to avoid dosing errors.

The Purity Caveat

None of these products carry a SAHPRA registration number. None publish batch-specific third-party HPLC (high-performance liquid chromatography) certificates of analysis on their public listings. Neither Body Pharm nor HD Labs appears as an identifiable licensed manufacturer on SAHPRA or CIPC records [10][11]. Marketing claims of "99% purity" are not independently verified against Eli Lilly's clinical-trial compound because no third-party testing is disclosed. Readers who want a registered Schedule 4 GLP-1 with traceable manufacturing can compare against the Body Pharm Semaglutide 6 Pen or HD Semaglutide 10 Pen instead.

Retatrutide Price in South Africa: ZAR Cost Breakdown

Retatrutide sells in South Africa for roughly R600 to R5,000 per unit depending on format and total milligrams. Vials offer the lowest cost-per-mg; pre-filled pens carry a convenience premium because they eliminate reconstitution steps. All prices below are from Beskinny.store as of mid-2026 [5]. Prices are subject to change and could not be cross-checked against other South African retailers because no comparable public pricing was located at time of writing.

Product	Price (ZAR)	Cost per mg
5 mg vial (33% off)	R600	R120
10 mg vial (original)	R900	R90
10 mg vial (current, 18% off)	R600	R60
HD Labs Retatrutide 10 mg	R1,650	R165
HD Labs Retatrutide 32 mg	R2,300	R72
HD Labs Retatrutide 32 Pen	R2,500	R78
Body Pharm Retatrutide 32 Pen	R3,200	R100
Body Pharm Retatrutide 64 Pen	R5,000	R78

How to Read These Numbers

The discounted 10 mg vial at R60/mg is the cheapest entry point. The Body Pharm 32 Pen at R100/mg is the most expensive per milligram among non-discounted listings because pens carry a convenience markup. For a user titrating 2 → 4 → 8 mg weekly per the NEJM Phase 2 schedule [7], a single 32 mg unit covers roughly 8 weeks of mid-range dosing (32 mg ÷ 4 mg average weekly dose = 8 weeks). Readers weighing this against a registered Schedule 4 GLP-1 can price-check the Body Pharm Semaglutide 6 Pen or HD Semaglutide 10 Pen on the same site for a direct rand comparison.

Retatrutide Dosage Guide: Phase 2 Trial Protocol Reference

The Phase 2 NEJM trial by Jastreboff et al. (2023) titrated retatrutide once weekly via subcutaneous injection, starting at 2 mg and escalating in 2–4 mg increments every 4 weeks to a maximum studied dose of 12 mg. This stepwise approach allowed the body to adapt to each dose level and reduced gastrointestinal side effects compared to rapid escalation [4]. The table below reproduces that schedule for reference only. It is not a personal dosing recommendation. Self-administering an unregistered compound without medical supervision carries real risk.

Phase 2 Clinical Trial Protocol Reference Only — Not Medical Advice

Target arm	Weeks 1–4	Weeks 5–8	Weeks 9–12	Weeks 13–16	Weeks 17–48 (maintenance)
1 mg	1 mg	1 mg	1 mg	1 mg	1 mg
4 mg	2 mg	4 mg	4 mg	4 mg	4 mg
8 mg	2 mg	4 mg	8 mg	8 mg	8 mg
12 mg	2 mg	4 mg	8 mg	12 mg	12 mg

Source: Jastreboff et al., NEJM Phase 2 trial and Supplementary Appendix, 2023 [4][5]. Some arms included a "slow titration" variant to reduce gastrointestinal side-effects [5].

Why the Titration Matters

GI adverse events tracked the dose almost linearly in the published results. Nausea reached roughly 66% at 12 mg, diarrhoea ~50%, vomiting ~40%, and study discontinuation due to adverse events climbed to 10–15% in the highest-dose arms versus low single digits on placebo because the three receptor agonisms compound GI effects [6]. Skipping the 4-week ramp by jumping straight to 8 or 12 mg is exactly what the trial protocol was designed to avoid. Pilot cohorts that escalated too quickly experienced intolerable nausea and vomiting. This is the failure mode most likely to send an unsupervised user to a casualty ward.

Route and Frequency

Retatrutide was administered as a once-weekly subcutaneous injection in the Phase 2 trial, the same route and cadence used by approved GLP-1 agonists. This frequency balances steady-state drug levels with patient convenience [4]. Readers who want a SAHPRA-registered, prescribable alternative with a known stability profile and pharmacist oversight can compare the Body Pharm Semaglutide 6 Pen or HD Semaglutide 10 Pen—semaglutide is a Schedule 4 medicine in South Africa; retatrutide is not [9]. Any decision to use retatrutide should involve a qualified clinician who can monitor titration, GI tolerance, heart rate, and pancreatic enzymes. Unsupervised escalation risks serious adverse events.

Retatrutide Side Effects: What the Trials Show

Retatrutide's documented side-effect profile is dominated by dose-dependent gastrointestinal events. Nausea reached ~66%, diarrhoea ~50%, vomiting ~40%, and constipation ~30% at the 12 mg weekly dose in the 48-week Phase 2 trial, versus single-digit to ~40% rates on placebo because the triple receptor agonism amplifies GI signalling [1][10]. These are the same class effects seen with semaglutide and tirzepatide, though the magnitudes at 8–12 mg run higher than typical GLP-1 monotherapy because the glucagon arm adds additional metabolic signalling. Most GI events in Jastreboff et al. (NEJM, 2023) were mild-to-moderate and clustered during the dose-escalation weeks. Discontinuations due to adverse events still hit 10–15% in the 8 mg and 12 mg arms because some participants could not tolerate the nausea [10]. The trial recorded modest, reversible heart-rate increases of a few beats per minute, consistent with glucagon agonism raising metabolic rate. Small rises in amylase and lipase occurred without confirmed pancreatitis cases. No medullary thyroid carcinoma signal was detected over 48 weeks, though that window is too short to rule out the long-latency risks flagged for the GLP-1 class generally [10].

The Glucagon Question

Retatrutide's glucagon receptor arm is what differentiates it from tirzepatide and raises theoretical concerns about hepatic glucose output, blood pressure, and lipid changes—glucagon is a counter-regulatory hormone that normally opposes insulin. The Phase 2 paper did not report excess hypoglycaemia in non-diabetic participants, which is consistent with GLP-1/glucagon balance. Glucagon-driven effects on long-term cardiovascular and hepatic endpoints remain unquantified pending Phase 3 readouts [1][5].

What the Trial Data Cannot Tell You

Every adverse-event number above comes from pharmaceutical-grade retatrutide manufactured under GMP (good manufacturing practice) for Eli Lilly's trial. South African research-peptide vials sold without published Certificates of Analysis [6] carry a separate, unquantified risk layer: endotoxin contamination, residual solvents, incorrect peptide content, or aggregation products. None of those risks appear in the NEJM safety tables because the trial did not use those products. If you want a regulated GLP-1 option with a known stability and impurity profile, the Body Pharm Semaglutide 6 Pen and HD Semaglutide 10 Pen are Schedule 4 prescription products with established adverse-event data. Retatrutide, in 2026, is not. Safety disclaimer: This section summarises published trial data. It is not medical advice. Anyone considering retatrutide should consult a registered South African medical practitioner before use. Stop immediately and seek care if persistent vomiting, severe abdominal pain, signs of pancreatitis, or symptoms of dehydration develop.

How to Buy Retatrutide Online in South Africa

Retatrutide is available from South African online vendors as a research peptide, not as a SAHPRA-registered medicine [4][5]. Buyers assume responsibility for compliance with the Medicines and Related Substances Act and any applicable import or use restrictions because the legal status remains ambiguous. This guide does not assert that purchase, possession, or self-administration is legal in your circumstances. Confirm your own position before ordering. The purchase flow at Beskinny.store is standard ecommerce: browse the weight-loss injections category, select a format, add to cart, and check out. Two product formats dominate:

• Pre-filled pens (e.g., Body Pharm Retatrutide 32 Pen, HD Labs Retatrutide 32) arrive ready to dial and inject, similar in handling to a semaglutide pen because they use the same click-dose mechanism.
• Lyophilised vials (e.g., Retatrutide 10mg) ship as freeze-dried powder and require reconstitution with bacteriostatic water before use because the peptide is unstable in solution and must be stored dry. Most vendors include or sell bac-water separately. The user calculates the injection volume based on the chosen weekly dose against the titration table earlier in this guide.

Neither format ships with a SAHPRA-reviewed patient information leaflet or a batch-specific Certificate of Analysis published on the product page [7][12]. If you would rather use a Schedule 4 prescription GLP-1 with established stability data, the Body Pharm Semaglutide 6 Pen and HD Semaglutide 10 Pen are the regulated alternatives.

Retatrutide vs Other Beskinny Weight-Loss Options

Retatrutide is the most mechanistically advanced injectable in Beskinny's catalogue but also the least clinically established. No published Phase 3 data exists and no SAHPRA registration exists as of mid-2026 because Eli Lilly is still running late-stage trials [7][15]. Every other weight-loss injectable on the site either targets fewer receptors or, in the case of semaglutide, sits inside the regulated Schedule 4 framework. The clearest comparison is against semaglutide, a single GLP-1 receptor agonist approved by SAHPRA as a Schedule 4 medicine. The Body Pharm Semaglutide 6 Pen and HD Semaglutide 10 Pen deliver a mechanism with years of Phase 3 outcome data behind it—semaglutide has been in clinical use since 2017. Retatrutide adds GIP and glucagon agonism on top of GLP-1 for potentially greater weight loss, at the cost of an ~80% GI adverse-event rate at 12 mg in the 2023 NEJM Phase 2 trial [14]. The HD Tirsema 44 Pen combines tirzepatide-style dual GLP-1/GIP action with semaglutide, sitting between single-agonist semaglutide and triple-agonist retatrutide on the mechanism ladder because it activates two receptors instead of one or three. Growth-hormone-axis peptides on the site solve a different problem entirely. The Body Pharm CJC1295 & Ipamorelin 20 Pen stimulates endogenous GH (growth hormone) release for body-composition changes rather than appetite suppression because it targets the growth-hormone axis instead of metabolic appetite pathways. The Body Pharm Tesamorelin 32 Pen is positioned for visceral fat reduction via GHRH (growth-hormone-releasing hormone) agonism because GHRH preferentially mobilises central adiposity. Neither competes directly with GLP-1 agonists on appetite or glycaemic control; they are adjuncts, not substitutes. Browse the full weight-loss injections category to weigh formats side by side.

Frequently Asked Questions About Retatrutide

Is retatrutide approved in South Africa?

No. Retatrutide is not registered with SAHPRA as of mid-2026 and does not appear on the human medicines database or the latest Schedules to the Medicines and Related Substances Act because no marketing application has been filed [5][6]. Local sellers market it as a research peptide, which sits in an unregistered, grey-zone category rather than an approved prescription medicine [7].

What is the difference between a retatrutide pen and a vial?

A vial contains lyophilised powder that the user reconstitutes with bacteriostatic water and draws into an insulin syringe because the peptide is unstable in solution. A pre-filled pen arrives already mixed and dosed by click because the manufacturer has stabilised the formulation. South African listings include both formats, including hybrid pens like the GLP1-2U Retrexa 44 mg (retatrutide 32 mg plus naltrexone 12 mg) [14].

How does retatrutide compare to semaglutide for weight loss?

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist; semaglutide acts on GLP-1 only. Phase 2 data (Jastreboff et al., NEJM, 2023) showed mean weight loss of ~24% at 48 weeks on 12 mg weekly retatrutide versus ~15% on high-dose semaglutide in comparable trials because the triple mechanism addresses appetite, insulin response, and energy expenditure simultaneously [10]. Semaglutide is SAHPRA-registered Schedule 4. See the Body Pharm Semaglutide 6 Pen or HD Semaglutide 10 Pen for the approved-mechanism alternative.

What dose of retatrutide was used in clinical trials?

The Jastreboff et al. NEJM 2023 Phase 2 trial tested 1, 4, 8, and 12 mg once weekly over 48 weeks, with stepwise titration every 4 weeks (e.g., 2→4→8→12 mg for the top arm) to limit GI side effects because rapid escalation produced intolerable nausea [10][11].

Can I get retatrutide on prescription in South Africa?

Not through normal prescription channels. Because retatrutide has no SAHPRA registration, a doctor cannot script it like semaglutide. Legal human use would require a Section 21 unregistered-medicine authorisation, which is rarely granted for elective weight loss because the regulator prioritises approved medicines [5][6][7].

How long does one pen or vial last?

A 5 mg vial covers roughly 5 weeks at a 1 mg maintenance dose or about 10 weeks during early titration because the titration phase uses lower weekly doses. Vendor handling notes suggest 30 days of refrigerated stability after reconstitution, in line with the 28–56 day post-first-use windows on approved GLP-1 pens like Ozempic because peptides degrade in solution over time [15][8][14].

Next Steps

If you are considering retatrutide, start by consulting a registered South African medical practitioner who can assess your health status, review the Phase 2 trial data, and discuss the regulatory and manufacturing uncertainties outlined in this guide. If you prefer a SAHPRA-registered alternative with established safety data, request a prescription for semaglutide or tirzepatide through your doctor, or browse the Body Pharm Semaglutide 6 Pen and HD Semaglutide 10 Pen on Beskinny.store. If you decide to source retatrutide as a research peptide, confirm the legal status with SAHPRA directly, verify the vendor's track record, and do not escalate doses faster than the Phase 2 titration schedule recommends. Monitor for GI symptoms, heart-rate changes, and signs of pancreatitis throughout use.